Halozyme Therapeutics vor neuem Allzeit-Hoch? - 500 Beiträge pro Seite

[Braggo2]

Halozyme Therapeutics (HTI): Biotechnologie-Firma, die durch Rekombination menschlicher Enzyme neue Wirkstoffe zur Behandlung von bspw. Unfruchtbarkeit und Krebs entwickeln möchte. Revolutionäre Technologie. Extrem viel versprechend aber auch sehr spekulativ. Aktie gehört zu den Topp-Performern 2006, ist aber immer noch relativ unentdeckt:



Die Aktie könnte nun in Richtung der alten Hochs laufen. Die Pressemitteilung ist wohl so ziemlich die am schwersten zu verstehende Meldung, die ich jemals gelesen habe. Biotech-Experten sind aber begeistert und der Kursverlauf der Aktie innerhalb der letzten 12 Monate spricht ebenfalls für sich:

SAN DIEGO, Jan 22, 2007 /PRNewswire-FirstCall via COMTEX/ — Halozyme Therapeutics, Inc. (HTI) , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced the results of a clinical trial of Enhanze(TM) Technology intended to measure the improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT). Enhanze Technology is Halozyme’s enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20).
This clinical trial compared the pharmacokinetics (PK), safety, and tolerability of an LPMT agent subcutaneously injected first without Enhanze Technology (rHuPH20) and then with rHuPH20 in 15 patients. The open-label, dose escalation, within-patient controlled study used escalating dose cohorts of rHuPH20 (ranging from 1,600 U to 12,800 U) and substituted a standard subcutaneous (SC) injection of the LPMT with one SC injection of the LPMT agent combined with Enhanze Technology (rHuPH20). The study compared the bioavailability and other PK parameters, along with safety and tolerability, of the two SC injections, one with and one without Enhanze Technology (rHuPH20). The data from this clinical trial support the study hypothesis that rHuPH20 increases the relative bioavailability of the LPMT.

Bin hier vorher zu 7,54 US-Dollar long gegangen.

[Braggo2]

Die Aktie könnte nun in Richtung der alten Hochs laufen. Die Pressemitteilung ist wohl so ziemlich die am schwersten zu verstehende Meldung, die ich jemals gelesen habe. Biotech-Experten sind aber begeistert und der Kursverlauf der Aktie innerhalb der letzten 12 Monate spricht ebenfalls für sich:

SAN DIEGO, Jan 22, 2007 /PRNewswire-FirstCall via COMTEX/ — Halozyme Therapeutics, Inc. (HTI) , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced the results of a clinical trial of Enhanze(TM) Technology intended to measure the improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT). Enhanze Technology is Halozyme’s enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20).
This clinical trial compared the pharmacokinetics (PK), safety, and tolerability of an LPMT agent subcutaneously injected first without Enhanze Technology (rHuPH20) and then with rHuPH20 in 15 patients. The open-label, dose escalation, within-patient controlled study used escalating dose cohorts of rHuPH20 (ranging from 1,600 U to 12,800 U) and substituted a standard subcutaneous (SC) injection of the LPMT with one SC injection of the LPMT agent combined with Enhanze Technology (rHuPH20). The study compared the bioavailability and other PK parameters, along with safety and tolerability, of the two SC injections, one with and one without Enhanze Technology (rHuPH20). The data from this clinical trial support the study hypothesis that rHuPH20 increases the relative bioavailability of the LPMT.

Bin hier vorher zu 7,54 US-Dollar long gegangen.

http://www.mastertraders.de/us-trading/